Iran’s Ambassador to China AbolReza Rahmani Fazli attends a press conference at the Iranian Embassy in Beijing on April 8. Photo: Hu Xuan/Caixin Iran signaled it is ready to open talks with the U.S. following a tentative ceasefire, while warning it would retaliate more forcefully if Washington abandons negotiations, Iran’s ambassador to China said Wednesday. AbolReza Rahmani Fazli told a press con...
Iran’s Ambassador to China AbolReza Rahmani Fazli attends a press conference at the Iranian Embassy in Beijing on April 8. Photo: Hu Xuan/Caixin Iran signaled it is ready to open talks with the U.S. following a tentative ceasefire, while warning it would retaliate more forcefully if Washington abandons negotiations, Iran’s ambassador to China said Wednesday. AbolReza Rahmani Fazli told a press conference in Beijing that Tehran would engage based on a 10-point peace plan it has proposed, which U.S. officials have indicated could serve as a workable framework.
Luis Alvarez American Eagle Outfitters ( AEO ) and Tesla ( TSLA ) have both received upgrades as Seeking Alpha analysts see improved risk-reward profiles following recent selloffs. On the downgrade side, Novo Nordisk ( NVO ) faces mounting concerns over clinical setbacks and intensifying GLP-1 competition, while Microsoft ( MSFT ) is being flagged for falling behind in the AI infrastructure race. ...
Luis Alvarez American Eagle Outfitters ( AEO ) and Tesla ( TSLA ) have both received upgrades as Seeking Alpha analysts see improved risk-reward profiles following recent selloffs. On the downgrade side, Novo Nordisk ( NVO ) faces mounting concerns over clinical setbacks and intensifying GLP-1 competition, while Microsoft ( MSFT ) is being flagged for falling behind in the AI infrastructure race. Tariff headwinds and geopolitical uncertainty continue to weigh on investor sentiment, but some analysts see these pressures as creating buying opportunities in beaten-down names. Upgrades American Eagle Outfitters ( AEO ): Upgrade Sell to Hold by Jay Capital . The analyst notes that Aerie’s strong 23% comp growth and early signs of stabilization in the American Eagle brand have weakened the previous bear case, with the stock now appearing fairly valued at 9.4x NTM P/E despite tariff headwinds. “I am upgrading AEO to a hold rating. I believe AEO fundamentals have improved vs. when I last wrote about it, and I think that is most visible in Aerie’s strong growth and the early signs of stabilization at the AE brand." Tesla ( TSLA ): Upgrade to Buy by The Techie . Following a significant 21.5% year-to-date selloff, the analyst believes the risk-reward profile has become favorable for a cautious entry, citing international growth catalysts and long-term optionality in autonomy and energy. “I’m upgrading the stock to a cautious Buy at current levels. I’m not trying to time the market here, but I think that if we get any resolution on the geopolitical and tariff fronts, even a partial one, Tesla is well positioned to snap back hard. The stock has historically been a high-beta vehicle on the way up, and that cuts in your favor when sentiment turns bullish.” Downgrades Novo Nordisk ( NVO ): Downgrade Buy to Sell by Terry Chrisomalis . The downgrade follows CagriSema’s clinical failure to outperform Eli Lilly’s tirzepatide, combined with looming patent cliffs and intensifying GLP-1 c...
Luis Alvarez American Eagle Outfitters ( AEO ) and Tesla ( TSLA ) have both received upgrades as Seeking Alpha analysts see improved risk-reward profiles following recent selloffs. On the downgrade side, Novo Nordisk ( NVO ) faces mounting concerns over clinical setbacks and intensifying GLP-1 competition, while Microsoft ( MSFT ) is being flagged for falling behind in the AI infrastructure race. ...
Luis Alvarez American Eagle Outfitters ( AEO ) and Tesla ( TSLA ) have both received upgrades as Seeking Alpha analysts see improved risk-reward profiles following recent selloffs. On the downgrade side, Novo Nordisk ( NVO ) faces mounting concerns over clinical setbacks and intensifying GLP-1 competition, while Microsoft ( MSFT ) is being flagged for falling behind in the AI infrastructure race. Tariff headwinds and geopolitical uncertainty continue to weigh on investor sentiment, but some analysts see these pressures as creating buying opportunities in beaten-down names. Upgrades American Eagle Outfitters ( AEO ): Upgrade Sell to Hold by Jay Capital . The analyst notes that Aerie’s strong 23% comp growth and early signs of stabilization in the American Eagle brand have weakened the previous bear case, with the stock now appearing fairly valued at 9.4x NTM P/E despite tariff headwinds. “I am upgrading AEO to a hold rating. I believe AEO fundamentals have improved vs. when I last wrote about it, and I think that is most visible in Aerie’s strong growth and the early signs of stabilization at the AE brand." Tesla ( TSLA ): Upgrade to Buy by The Techie . Following a significant 21.5% year-to-date selloff, the analyst believes the risk-reward profile has become favorable for a cautious entry, citing international growth catalysts and long-term optionality in autonomy and energy. “I’m upgrading the stock to a cautious Buy at current levels. I’m not trying to time the market here, but I think that if we get any resolution on the geopolitical and tariff fronts, even a partial one, Tesla is well positioned to snap back hard. The stock has historically been a high-beta vehicle on the way up, and that cuts in your favor when sentiment turns bullish.” Downgrades Novo Nordisk ( NVO ): Downgrade Buy to Sell by Terry Chrisomalis . The downgrade follows CagriSema’s clinical failure to outperform Eli Lilly’s tirzepatide, combined with looming patent cliffs and intensifying GLP-1 c...
ronniechua/iStock via Getty Images About five and a half years ago, I recommended buying Sabine Royalty Trust ( SBR ) for its exceptional business performance and my expectations for a strong recovery from the pandemic. The stock has vastly outperformed the S&P 500 since that article, as it has offered a total return of 329%, whereas the S&P 500 has doubled. I reiterated my bullish thesis about si...
ronniechua/iStock via Getty Images About five and a half years ago, I recommended buying Sabine Royalty Trust ( SBR ) for its exceptional business performance and my expectations for a strong recovery from the pandemic. The stock has vastly outperformed the S&P 500 since that article, as it has offered a total return of 329%, whereas the S&P 500 has doubled. I reiterated my bullish thesis about six months later for similar reasons. Since then, the stock has offered a total return of 285%, whereas the S&P 500 has gained 64%. Due to the steep rally of Sabine Royalty Trust after these two articles, I lowered my rating from “buy” to “hold” in the fall of 2021. However, the change of the rating proved premature, as the oil and gas trust has offered a total return of 190% since that article (vs. +47% of the S&P 500). About three and a half years ago, I recommended selling Sabine Royalty Trust, primarily due to my expectations that the price of oil would incur a sharp decrease off the highs it recorded shortly after the invasion of Russia in Ukraine. Indeed, the stock has pronouncedly underperformed the broad market since that article, as it has offered a total return of only 31%, whereas the S&P 500 has advanced 75%. Since then, I have reiterated my sell rating five times with similar success, with the exception of the last two times. Since I reiterated my sell rating in mid-2024 and in September 2024 , Sabine Royalty Trust has outperformed the S&P 500 by 11% and 24%, respectively. The outperformance has resulted not only from the unforeseeable war in Iran but also from the strong business performance of the oil and gas trust (more on this later). The big question is whether Sabine Royalty Trust is attractive or investors should look elsewhere for great returns. Business overview Sabine Royalty Trust is a high-quality oil and gas trust, which was founded in 1983 and has royalty interests in properties in Florida, Louisiana, Mississippi, New Mexico, Oklahoma, and Texas. At...
Anthropic Withholds Latest Model After It Went Rogue In Testing; Launches "Project Glasswing" To Secure Critical Software Still smarting from its embarrassing source code leak, Anthropic announced it will not release its latest frontier AI model, Mythos, to the public, saying the model is too powerful in ways that introduce elevated cybersecurity risk. In internal testing, Anthropic said the model...
Anthropic Withholds Latest Model After It Went Rogue In Testing; Launches "Project Glasswing" To Secure Critical Software Still smarting from its embarrassing source code leak, Anthropic announced it will not release its latest frontier AI model, Mythos, to the public, saying the model is too powerful in ways that introduce elevated cybersecurity risk. In internal testing, Anthropic said the model surfaced thousands of high‑severity “zero‑day” vulnerabilities (previously unknown flaws) across every major operating system and web browser, materially outperforming its prior flagship (CyberGym vulnerability reproduction: 83.1% vs. 66.6% for Opus 4.6). “Given the rate of AI progress, it will not be long before such capabilities proliferate, potentially beyond actors who are committed to deploying them safely.” A zero-day vulnerability is a software bug that can be exploited before anyone with the ability to fix it even knows it exists. Finding and patching them has historically required rare, expensive human expertise, but AI could change the scale and speed of detection. Anthropic said the vulnerabilities it finds are “often subtle or difficult to detect.” Many of them are 10 or 20 years old, with the oldest found so far being a now-patched 27-year-old bug in OpenBSD — an operating system known primarily for its security, it added. It also found a 16-year-old bug in the FFmpeg media processing library, a 17-year-old remote code execution vulnerability in the open-source FreeBSD operating system and numerous vulnerabilities in the Linux kernel. Mythos Preview also identified several weaknesses in the world’s most popular cryptography libraries, algorithms and protocols, including TLS, AES-GCM and SSH. It added that web applications “contain a myriad of vulnerabilities,” ranging from cross-site scripting and SQL injection to domain-specific vulnerabilities such as cross-site request forgery, which is often used in phishing attacks . Lifecycle of a zero-day exploit. Sourc...
juststock/iStock via Getty Images Investment Approach Fidelity® Corporate Bond Fund ( FCBFX ) is a credit-focused bond strategy that seeks a high level of current income. Benchmarked against the Bloomberg U.S. Credit Bond Index, the fund seeks to deliver competitive risk-adjusted performance commensurate with investor expectations of a primarily investment-grade corporate bond fund. Utilizing a te...
juststock/iStock via Getty Images Investment Approach Fidelity® Corporate Bond Fund ( FCBFX ) is a credit-focused bond strategy that seeks a high level of current income. Benchmarked against the Bloomberg U.S. Credit Bond Index, the fund seeks to deliver competitive risk-adjusted performance commensurate with investor expectations of a primarily investment-grade corporate bond fund. Utilizing a team-based investment process, the fund relies on experienced portfolio managers, research analysts and traders. We concentrate on areas where we believe we can repeatedly add value, including security selection, industry allocation and opportunistic trading. Robust governance and risk management – consisting of extensive quantitative modeling, formal and informal portfolio reviews, and proprietary tools – support the identification of both opportunities and risks. Performance Summary Cumulative Cumulative Annualized Annualized Annualized Annualized 3 Month YTD 1 Year 3 Year 5 Year 10 Year/ LOF 1 Fidelity Corporate Bond FundGross Expense Ratio: 0.45% 2 0.79% 7.84% 7.84% 6.45% -0.09% 3.42% Bloomberg US Credit Bond Index 0.87% 7.83% 7.83% 5.98% -0.05% 3.15% Lipper Corporate Debt BBB-Rated Funds Classification 0.69% 7.23% 7.23% 5.70% -0.47% 2.96% Morningstar Fund Corporate Bond 0.78% 7.65% 7.65% 6.26% 0.25% 3.23% Click to enlarge 1 Life of Fund (LOF) if performance is less than 10 years. Fund inception date: 05/04/2010. 2 This expense ratio is from the most recent prospectus and generally is based on amounts incurred during the most recent fiscal year, or estimated amounts for the current fiscal year in the case of a newly launched fund. It does not include any fee waivers or reimbursements, which would be reflected in the fund's net expense ratio. Past performance is no guarantee of future results. Investment return and principal value of an investment will fluctuate; therefore, you may have a gain or loss when you sell your shares. Current performance may be higher or lower th...
We are exiting our position in Bristol Myers Squibb , selling 1,100 shares at roughly $58.94. In addition, we are initiating a new position in Johnson & Johnson , buying 150 shares at roughly $237.65. Following the two trades, Jim Cramer's Charitable Trust will no longer own a position in BMY and will own 145 shares of JNJ, representing about 1% of the portfolio. We're making a pharmaceutical swap...
We are exiting our position in Bristol Myers Squibb , selling 1,100 shares at roughly $58.94. In addition, we are initiating a new position in Johnson & Johnson , buying 150 shares at roughly $237.65. Following the two trades, Jim Cramer's Charitable Trust will no longer own a position in BMY and will own 145 shares of JNJ, representing about 1% of the portfolio. We're making a pharmaceutical swap Wednesday. We're hanging onto a small gain of 3.5% in what's left of our Bristol Myers position, and we don't want to stick around and risk turning into a loss. Bristol Myers had a disappointing first 10 months of 2025, dragged down by pharmaceutical-tariff worries and a missed late-stage Cobenfy trial evaluating its use as an adjunctive treatment for atypical antipsychotics in adults with schizophrenia. But the stock has come alive over the last six months, rallying roughly 30% as tariffs threats eased and investors looked beyond Cobenfy in the pipeline. Bristol Myers has several key pipeline readouts expected this year, and the success of these trials will be critical to navigating its upcoming patent cliff. We're not making a call on any individual outcome; instead, we prefer to focus on commercial excellence rather than binary events. Which brings us to Johnson & Johnson, which had been in our Bullpen watchlist. Bristol Myers has held a slight edge over the past six months, with its roughly 30% gain outpacing Johnson & Johnson's 25% return over the same period. So, it's been right to hang onto Bristol Myers during this period. However, the longer-term picture favors J & J, which has rallied about 58% over the past year compared with Bristol Myers' more modest 10% advance. J & J generated about $94 billion in sales in 2025, with roughly two-thirds coming from its pharmaceutical division, known as Innovative Medicines, and the other third from its medical products segment, known as MedTech. Innovative Medicines sales increased 5.3% year over year in 2025, driven by doubl...
Antares Nuclear Inc. , a California-based startup developing small reactors, has won approval from federal regulators to complete its demonstration system — the first company granted such authorization under a US program aimed at accelerating new fission technologies. The company has already built its Mark-0 microreactor and is preparing to load fuel in the coming months, Chief Executive Officer J...
Antares Nuclear Inc. , a California-based startup developing small reactors, has won approval from federal regulators to complete its demonstration system — the first company granted such authorization under a US program aimed at accelerating new fission technologies. The company has already built its Mark-0 microreactor and is preparing to load fuel in the coming months, Chief Executive Officer Jordan Bramble said in an interview. That puts Antares on track to reach a key milestone for participants in the US Energy Department’s reactor pilot program. The department announced the program last year, part of the Trump administration’s efforts to promote wider use of nuclear energy. The goal is for at least three projects to achieve criticality by July 4, a significant technical achievement marked by a self-sustaining nuclear chain-reaction. Antares received approval for its documented safety analysis Monday, the first of the 10 firms in the pilot program to do so, according to the company. Bramble expects the system to begin producing electricity in 2027. “It’s essentially the final regulatory signoff,” he said.
(RTTNews) - PMGC Holdings Inc. (ELAB) shares rose 28.66 percent, up $0.9901 to $4.4401 on Wednesday, after the company said it had fully utilized its $20 million equity purchase facility with Streeterville Capital, LLC.
(RTTNews) - PMGC Holdings Inc. (ELAB) shares rose 28.66 percent, up $0.9901 to $4.4401 on Wednesday, after the company said it had fully utilized its $20 million equity purchase facility with Streeterville Capital, LLC.
The S&P 500 Index ($SPX ) (SPY ) today is up +2.04%, the Dow Jones Industrial Average ($DOWI ) (DIA ) is up +2.25%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is up +2.52%. June E-mini S&P futures (ESM26 ) are up +2.17%, and June E-mini Nasdaq futures...
The S&P 500 Index ($SPX ) (SPY ) today is up +2.04%, the Dow Jones Industrial Average ($DOWI ) (DIA ) is up +2.25%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is up +2.52%. June E-mini S&P futures (ESM26 ) are up +2.17%, and June E-mini Nasdaq futures...
Krot Studio Databricks co-founder and CTO Matei Zaharia said that artificial general intelligence, the form of AI that surpasses humanity, is “here already.” “AGI is here already. It’s just not in a form that we appreciate,” Zaharia said in an interview with TechCrunch . “I think the bigger point of it is: we should stop trying to apply human standards to these AI models.” Artificial general intel...
Krot Studio Databricks co-founder and CTO Matei Zaharia said that artificial general intelligence, the form of AI that surpasses humanity, is “here already.” “AGI is here already. It’s just not in a form that we appreciate,” Zaharia said in an interview with TechCrunch . “I think the bigger point of it is: we should stop trying to apply human standards to these AI models.” Artificial general intelligence, sometimes also known as general artificial intelligence, has been previously described as the singularity—an event where technology surpasses humanity and becomes irreversible. In 2023, SoftBank ( SFTBY ) Chief Executive Officer Masayoshi Son said general artificial intelligence would top the collective intelligence of humanity and come within the next 10 years. Other tech executives, such as OpenAI ( OPENAI ) board member and Quora co-founder and CEO Adam D'Angelo, said the introduction of general artificial intelligence will be a “very, very important change in the world when we get there.” Databricks operates in the data warehousing and data analytics market and competes with Snowflake ( SNOW ). In December, Databricks raised more than $4B in its Series L investment round, which valued the company at $134B. The company also said that it crossed a $4.8B revenue run rate during its fiscal third-quarter, up more than 55% year over year. In January, it was reported that Databricks added nearly $1.8B in new debt financing. It increased the size of its term loan to $1.15B from $500M and increased the size of its revolving loan to $3.65B, up from $2.5B. More on Snowflake Snowflake: Agentic AI And Data Cloud Winner - Upgrade To Speculative Buy Snowflake: Cheap Enough To Watch, Not Yet Cheap Enough To Buy Snowflake: It Would Be Wise To Stay On The Sidelines Datadog, Snowflake seen 'accelerating' growth as AI spending continues: BofA Notable analyst calls this week: UnitedHealth, Akamai and Snowflake among top picks
The U.S. military’s recent Operation Absolute Resolve put F-35s, F-22s, and stealth drones into live combat, and every platform traced back to a company inside Global X Defense Tech ETF (NYSEARCA:SHLD). Modern warfare runs on software, sensors, and precision hardware, and SHLD is built to capture the companies building all three. Concentrated Defense Exposure by ... How Defense Tech Investors Are ...
The U.S. military’s recent Operation Absolute Resolve put F-35s, F-22s, and stealth drones into live combat, and every platform traced back to a company inside Global X Defense Tech ETF (NYSEARCA:SHLD). Modern warfare runs on software, sensors, and precision hardware, and SHLD is built to capture the companies building all three. Concentrated Defense Exposure by ... How Defense Tech Investors Are Using SHLD to Capture 21st Century Warfare Spending